Yang Dong-Kun, Nah Jin-Ju, Kim Ha-Hyun, Song Jae-Young
Viral Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA), Anyang, Korea.
Clin Exp Vaccine Res. 2014 Jul;3(2):212-9. doi: 10.7774/cevr.2014.3.2.212. Epub 2014 Jun 20.
Japanese encephalitis is a reproductive disorder caused by Japanese encephalitis virus (JEV) in swine. Recent genotype (G) shift phenomenon (G3 to G1) in the Asia-wide has posed a challenge for proper prevention by the current vaccine strain. Thus, new kinds of JEV G1 vaccines with enhanced immunogenicity have been required for pigs.
Recombinant porcine granulocyte monocyte-colony stimulating factor (reporGM-CSF) protein was expressed in Spodoptera frugiperda (Sf-9) cells using baculovirus expression system. Two kinds of trials with inactivated JEV vaccines containing IMS1313 adjuvant (Seppic, France) were prepared with or without reporGM-CSF protein. Safety and immunogenicity of the pigs inoculated with the JEV vaccines via intramuscular route was evaluated for 28 days after inoculation.
Mice, guinea pigs, and fattening pigs inoculated with the inactivated vaccine showed no signs for 14 and 21 days. Both hemagglutination inhibition and plaque reduction neutralizing antibody titers were significantly higher in pigs immunized with the vaccine containing reporGM-CSF protein after boosting. However, on the side of vaccine efficacy, most mice (87%) immunized with the inactivated JEV vaccine survived after virulent JEV challenge. Whereas the group with the vaccine containing reporGM-CSF protein showed lower protective effects than the vaccine alone for the biological activity of the GM-CSF depending on species specific.
Our data indicate that animals inoculated with the JEV vaccines was safe and pigs inoculated with inactivated JEV vaccine containing reporGM-CSF protein showed higher humoral immune responses than that of inactivated JEV vaccine without reporGM-CSF protein.
日本脑炎是由日本脑炎病毒(JEV)引起的猪繁殖障碍疾病。近期亚洲范围内出现的基因型(G)转变现象(从G3到G1)对当前疫苗株的有效预防构成了挑战。因此,需要为猪研发具有增强免疫原性的新型JEV G1疫苗。
使用杆状病毒表达系统在草地贪夜蛾(Sf-9)细胞中表达重组猪粒细胞巨噬细胞集落刺激因子(reporGM-CSF)蛋白。制备了两种含IMS1313佐剂(法国赛比克公司)的灭活JEV疫苗,一种含reporGM-CSF蛋白,另一种不含。通过肌肉注射途径接种JEV疫苗的猪,在接种后28天评估其安全性和免疫原性。
接种灭活疫苗的小鼠、豚鼠和育肥猪在14天和21天内均无异常迹象。加强免疫后,接种含reporGM-CSF蛋白疫苗的猪的血凝抑制和蚀斑减少中和抗体效价均显著更高。然而,在疫苗效力方面,接种灭活JEV疫苗的大多数小鼠(87%)在受到强毒JEV攻击后存活。而含reporGM-CSF蛋白疫苗组根据物种特异性,其GM-CSF的生物学活性显示出比单独疫苗更低的保护效果。
我们的数据表明,接种JEV疫苗的动物是安全的,接种含reporGM-CSF蛋白的灭活JEV疫苗的猪比接种不含reporGM-CSF蛋白的灭活JEV疫苗的猪表现出更高的体液免疫反应。